Prostate cancer remains the most common non-skin cancer malignancy in men. Prostate-specific antigen (PSA) is recognized as a biomarker for the diagnosis, monitoring, and risk prediction of prostate cancer. Its use in the setting of prostate cancer screening has been controversial due to the risk of over diagnosis and over treatment. According to the American Cancer Society, a man's total PSA number usually goes above 4.0 ng/mL when prostate cancer develops, and having a PSA higher than 10 ng/mL means you have over a 50 Screening for prostate cancer using PSA has been shown to reduce prostate cancer mortality, but its utility is highly age dependent. a large multicenter trial that compared the accuracy of the TRUS-guided biopsy and the mpMRI against a reference test, prostate cancer with a pooled sensitivity of 72% and pooled specificity of 96%. The 1. Introduction. Prostate carcinoma is a common disease that occurs in men over 50 years old; serum prostate-specific antigen (PSA), which is produced by all types of prostate tissue, is one of the most important biomarkers for detecting prostate cancer, guiding decisions about biopsies of the prostate and offering a way to monitor disease progression. Half of the participants were offered prostate-specific antigen (PSA) blood tests while the others were initially offered DRE with delayed PSA screening at age 50. This study aimed to evaluate the usefulness of ultra-sensitive prostate-specific antigen (PSA) following radical prostatectomy (RP). Between September, 2003 and March, 2009, a total of 311 prostate cancer patients underwent antegrade RP; following the exclusion of 111 patients due to prior hormonal therapy, 200 patients were finally included in Result LOINC Value. Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure. PSAU. PSA, Ultrasensitive, S. 35741-8. Monitoring disease after radical prostatectomy This test should not be used for initial prostate Life expectancy for men with localized prostate cancer can be as high as 99% over 10 years if diagnosed at an early stage 15. This long survival can largely be attributed to improvements in lead The Canadian Urological Association recommends screening with both DRE and PSA in all average-risk men aged 50 years and older with a minimum life expectancy of 10 years. 7 In contrast, the Canadian Task Force on Preventive Health Care recommends against use of the PSA test for prostate cancer screening in men aged 55 years or older without a Although DRE has high specificity for prostate cancer, it has a low sensitivity profile and is not considered an effective detection tool on its own. 108 In contemporary series, 109 PSA testing with a threshold of 4.0 ng/mL has a sensitivity of only about 20%. Although the sensitivity of PSA testing could be improved by lowering the threshold MYZW.